title: [Cefoperazone in the treatment of infections in newborn infants].
abstract: The authors evaluated clinically cefoperazone (Cefobid-Pfizer)--an antibiotic of the III generation of cephalosporins--administering it in the form of monotherapy to 32 infected neonates and premature babies. A complete recovery was achieved im 25 neonates, i.e. 78.1%, out of which 76.5% were generalized infections. The result of therapy was doubtful in the remaining 7 babies (21.9%). The drug was changed or the second antibiotic added. No decidedly unfavourable results (deaths) or adverse reactions necessitating withdrawal of the drug were observed. The authors compare this favourable results with the mortality rate of neonates prior to the introduction of the II and III generation cephalosporins. It was about 14%, then. Therefore, both +antibiotic monotherapy and cefoperazone enabling its use are worth wide popularization in neonates and small babies.
authors.forename: I
authors.initials: I
authors.lastname: Krzeska
authors.forename: W
authors.initials: W
authors.lastname: Galczak
authors.forename: W
authors.initials: W
authors.lastname: Mikołajczyk
authors.forename: W
authors.initials: W
authors.lastname: Duchiński
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002438:Cefoperazone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male
chemical_list: D002438:Cefoperazone
vernacular_title: Cefoperazon w leczeniu zakazeń u noworodków.